Posts Tagged ‘nonalcoholic fatty liver disease’

Our Top 10 Abstracts Going into ObesityWeek

November 1, 2022 — Today marks the actual opening of ObesityWeek 2022 in San Diego. So to help you wade through the many hundreds for research studies being presented this week, here is a list of the top ten abstracts at ObesityWeek. Make no mistake. This is a highly subjective list, but it’s ours. Every one of you reading […]

How BMI Can Miss Unhealthy Fat in the Liver

May 18, 2022 — One of the important complications of obesity is NAFLD – non-alcoholic fatty liver disease. Quite simply, this is a condition where unhealthy fat accumulates in the liver. It leads to inflammation and fibrosis, progressing to cirrhosis, liver cancer, or liver failure in severe cases. Often, it goes undetected until these more severe problems emerge. Because […]

Cutting NASH Harms by 88% with Bariatric Surgery

November 12, 2021 — NASH (non-alcoholic steatohepatitis) is one of the most serious complications of untreated obesity. It’s very hard to treat. It can lead to liver failure, liver cancer, and death. So when a careful study of bariatric surgery shows an an 88 percent reduction in the risk of NASH progressing, this is big news. JAMA published this […]

Fatty Liver, Obesity, and COVID-19

July 2, 2020 — Sometimes, a health crisis serves to clear the mind and prompt scientific curiosity. In fact, we see that in a steady stream of new research building an understanding of how COVID-19 leaves some people unharmed and others devastated. A new paper in Obesity offers a fine example. Ming Deng and colleagues bring new insights to […]

The Tortured Pathway for a New NASH Treatment

June 30, 2020 — It’s tough getting good information these days. Good, factual information. Everybody wants to spin it. That’s undeniable in public policy. But it also seems to be true in drug development. Yesterday, the FDA definitively rejected an application from Intercept Pharmaceuticals for a new drug to treat NASH – nonalcoholic steatohepatitis. The company was shocked. Its […]

Semaglutide Hits a Milestone in NASH

May 7, 2020 — Nonalcoholic steatohepatitis – NASH – is a more severe form of fatty liver disease that can lead to cirrhosis and liver cancer. Like other complications of obesity, people can develop NASH even if their BMI does not fall into the range of obesity. Just like obesity, the prevalence of NASH is growing and the treatment […]

Moving Beyond the Biopsy in NAFLD

December 24, 2018 — In all of the talk about the complications of obesity, much of the focus is on type 2 diabetes. But the health threat may be just as big – or even bigger – from non-alcoholic fatty liver disease (NAFLD). And it can start at an early age. A big part of the problem is that it often goes […]

Liver Function Improves after Bariatric Surgery

December 14, 2017 — Many people think obesity is all about weight and height and BMI. To them, we suggest pausing to think about the liver. Everyone has one. No one can live without it. And in obesity, liver function suffers. But with a new study published in Diabetes Care, we find some encouragement. Researchers found that six months […]

Obesity: A Hostile Takeover of Liver Disease

June 17, 2014 — Liver disease is being taken over by obesity. Nonalcoholic fatty liver disease is now the third most common reason for liver transplantation and it’s on track to be the leading cause soon. The chief of liver transplantation at UCLA, Ronald Busuttil, recently told the New York Times: I’m really afraid that the explosion of this condition […]